Pfizer Signals Renewed Obesity Research Interest

After abandoning research on obesity treatments several years ago when many of its big pharma peers did, Pfizer has reversed itself and invested $8 million in Rhythm, a biotech company with a small-peptide therapeutic in the pipeline for diabetes and obesity. 

Pfizer Venture Investments, Pfizer’s venture capital arm, joins a number of other investors who have put in a total of $73 million within the last two years.

“The obesity and diabetes epidemics represent one of the largest medical challenges confronting society today,” said Dr. Barbara Dalton, Vice President Venture Capital, Pfizer Venture Investments. “Rhythm’s metabolic programs are compelling because of the initial proof-of-concept data from ongoing clinical programs, along with the fact that peptide therapeutics have delivered high success rates in clinical development. We are pleased to help Rhythm capitalize on their opportunities.”

Click here to read the story in Fierce Biotech and here to read the press release from Rhythm .

Logo is a trademark of Pfizer, Inc.